<DOC>
	<DOCNO>NCT02204722</DOCNO>
	<brief_summary>This study evaluate efficacy safety Imatinib two group patient ; patient diagnose less 3 month chronic myeloid leukemia chronic phase . The group A , reference group , 10 % le 10 % BCR-ABL level three month dose maintain dose 400mg/day . On hand , group B , 10 % dose increase 400mg/day 600mg/day . The superiority group B prove evaluate MMR rate two group 12 month administeration Imatinib .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Glinib Newly Diagnosed CML Patients</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>age 18 newly diagnose within three month Chronic Myeloid Leukemia positive Philadelphia chromosome appearance BCRABL transcript 0 2 ECOG Performance Status normal renal function normal hepatic function able understand decide involve study history radiation therapy 25 % bone marrow due malignant disease history clinically relevant malignant tumor bleed disorder related leukemia evidence clinically relevant cardiac dysfunction severe disease regulate organ previous administration Imatinib week prior first dose . participation drug study ( eg . intervention trial ) within 30 day prior screen visit HIVinfected female pregnancy , childbearing lactate potential reason determine investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>